GeNeuro presents data supporting pathogenic role of an endogenous retroviral protein (HERV-W ENV) in post-COVID neuropsychiatric syndrome Enters collaboration with the FondaMental Foundation to speed development of diagnostic and therapeutic…
Paris, France and Geneva, Switzerland, July 5, 2021 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), presented new data showing that the neuropsychiatric symptomatology seen in “post-COVID” patients may be due to activation of HERV-W ENV expression in […]